Literature DB >> 10899078

Regulation of myocardial [(13)C]glucose metabolism in conscious rats.

P H McNulty1, G W Cline, J M Whiting, G I Shulman.   

Abstract

Administration of supplemental glucose and/or insulin is postulated to improve the outcome from myocardial ischemia by increasing the heart's relative utilization of glucose as an energy substrate. To examine the degree to which circulating glucose and insulin levels actually influence myocardial substrate preference in vivo, we infused conscious, chronically catheterized rats with D-[1-(13)C]glucose and compared steady-state (13)C enrichment of plasma glucose with that of myocardial glycolytic ([3-(13)C]alanine) and oxidative ([4-(13)C]glutamate) intermediary metabolites. In fasting rats, [3-(13)C]alanine-to-[1-(13)C]glucose and [4-(13)C]glutamate-to-[3-(13)C]alanine ratios averaged 0.16 +/- 0.12 and 0.14 +/- 0.03, respectively, indicating that circulating glucose contributed 32% of myocardial glycolytic flux, whereas subsequent flux through pyruvate dehydrogenase contributed 14% of total tricarboxylic acid (TCA) cycle activity. Raising plasma glucose to 11 mmol/l, or insulin to 500 pmol/l, increased these contributions equivalently. At supraphysiological (>6,500 pmol/l) insulin levels, the plasma glucose contribution to glycolysis increased further, and addition of hyperglycemia made it the sole glycolytic substrate, yet [4-(13)C]glutamate-to-[3-(13)C]alanine ratios remained </=0.60. Thus plasma levels of glucose and insulin independently regulate the proportional contribution of exogenous glucose to myocardial glycolytic and TCA cycle flux in vivo in a dose-dependent manner. However, even at supraphysiological levels, nonglucose substrates continue to supply >/=40% of myocardial TCA cycle flux.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899078     DOI: 10.1152/ajpheart.2000.279.1.H375

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  5 in total

Review 1.  Cardiac carbon 13 magnetic resonance spectroscopy: on the horizon or over the rainbow?

Authors:  E Douglas Lewandowski
Journal:  J Nucl Cardiol       Date:  2002 Jul-Aug       Impact factor: 5.952

Review 2.  Imaging of myocardial metabolism.

Authors:  Pilar Herrero; Robert J Gropler
Journal:  J Nucl Cardiol       Date:  2005 May-Jun       Impact factor: 5.952

3.  Myocardial oxidative metabolism and protein synthesis during mechanical circulatory support by extracorporeal membrane oxygenation.

Authors:  Colleen M O'Kelly Priddy; Masaki Kajimoto; Dolena R Ledee; Bertrand Bouchard; Nancy Isern; Aaron K Olson; Christine Des Rosiers; Michael A Portman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-11-30       Impact factor: 4.733

4.  Rosiglitazone Ameliorates Cardiac and Skeletal Muscle Dysfunction by Correction of Energetics in Huntington's Disease.

Authors:  Marta Tomczyk; Alicja Braczko; Paulina Mierzejewska; Magdalena Podlacha; Oliwia Krol; Patrycja Jablonska; Agata Jedrzejewska; Karolina Pierzynowska; Grzegorz Wegrzyn; Ewa M Slominska; Ryszard T Smolenski
Journal:  Cells       Date:  2022-08-27       Impact factor: 7.666

5.  In vivo [U-13C]glucose labeling to assess heart metabolism in murine models of pressure and volume overload.

Authors:  Moritz Schnelle; Mei Chong; Anna Zoccarato; Manar Elkenani; Greta Jane Sawyer; Gerd Hasenfuss; Christian Ludwig; Ajay M Shah
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-07-10       Impact factor: 4.733

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.